NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Gelteq Limited (GELS) Stock Analysis

Gelteq Limited (GELS) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

GELS

$0.90

+$0.01 (+0.78%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GELS with… →

GELS Key Statistics

As of Sep 4, 2026
Trading
Open
$0.81
Previous Close
$0.89
Day's Range
0.77–0.90
52-Week Range
0.39–2.01
Volume
1.44M
Valuation
Market Cap
$9.64M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
20.43
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.53
Financials (FY)
Revenue (FY)
$165.65K
Net Income (FY)
−$6.65M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
10.71M
1-Year Return
−6.25%
Dividend and dates
Avg Volume
5.96M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GELS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+12.50%
2025−65.52%
2024 (partial year)−21.09%

As of September 4, 2026.

GELS Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$165.65K−$6.65M−4011.9%
2024$0.00−$3.55M—
2023$79.84K−$3.51M−4391.4%
2022$147.54K−$3.37M−2283.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$165.65K—−$4.95M−$6.65M−4011.9%
2024$0.00$0.00−$2.61M−$3.55M—
2023$79.84K$30.92K−$3.38M−$3.51M−4391.4%
2022$147.54K$52.66K−$3.19M−$3.37M−2283.4%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

GELS Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricGELSDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio20.432.308.9x the median
Profit margin0.00%−3.14%3.1 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Gelteq Limited (GELS) carries a market capitalisation of $9.64M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 7.

The most recent close on file for GELS is $0.90, dated September 4, 2026. That is +$0.01 (+0.78%) against the previous close. The 52-week range on file runs from $0.39 to $2.01. The latest close sits 132.56% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $165.65K. The same year closed with a net loss of $6.65M. Profit margin runs at 0%. That is 3.1 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.53.

Across the 4 fiscal years on file, revenue moves from $147.54K in 2022 to $165.65K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 20.43. On price-to-sales that is 8.9 times the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year price return is −6.25%. The stored price history starts on October 29, 2024, and the total return since then is −69.39%. Annualized volatility over the trailing 1 year is 235.9%.

Growth & Income

No dividend is on file for GELS.

The record holds one complete calendar year, 2025, which returned −65.52%. 2026 is still running; the price is +12.50% year to date.

Peer Comparison

Gelteq Limited (GELS) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Gelteq Limited GELS $9.64M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Gelteq Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Gelteq Limited

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.

Visit website →